In one male-mouse 6-OHDA lesion study, systemic isradipine pretreatment did not rescue substantia nigra TH-positive dopamine-neuron loss versus placebo in the analyzed cohort with terminal plasma concentrations ≥3 ng/ml. This negative result is specific to the tested model and exposure conditions. [1]
In a separate juvenile-mouse study, systemic isradipine for 7–10 days reduced dendritic calcium oscillations measured ex vivo without a discernible change in autonomous dopamine-neuron pacemaking. Calcium oscillations returned to control levels 5–7 days after pump removal. These findings demonstrate a physiological response under those conditions; they do not establish neuronal survival benefit. [3]
No neuroprotection in the tested mouse lesion model
Animal study · Male C57BL/6 wild-type mice, 12–15 weeks old; unilateral 6-OHDA nigrostriatal lesion model [1]
In the analyzed cohort with terminal plasma ISR concentrations ≥3 ng/ml, systemic pretreatment did not rescue TH+ SN dopamine-neuron loss compared with placebo.
Conditions shared by the study groups
- Route
- Pellet implantation or subcutaneous osmotic minipumps
- Frequency
- Sustained-release administration
- Treatment course
- Started 7 days before lesion; TH+ neuronal survival assessed 28 days after lesion
- Vehicle
- Minipump vehicle: DMSO/PEG300; pellet carrier composition not specified in selected text
- Pooled systemic isradipine treatment
- Model: Male C57BL/6 wild-type mice, 12–15 weeks old; unilateral 6-OHDA nigrostriatal lesion model
- Reported limits: Outcomes are pooled across delivery regimens; no dose-specific efficacy inferred. Continuous pump delivery through the full assessment period is not independently established in the selected text.
Methods and source locations
Compound reported in the paper: Isradipine; Compound label in the paper: ISR
Applies to the named isradipine tested in this model. No salt conversion, stereoisomer equivalence or validation of the current Adooq lot is inferred.
Results first subsection; Figure 1B,D,E; Methods Animals, Isradipine treatment and plasma concentration measurement
TH+ substantia nigra dopamine neurons remaining on lesioned side relative to nonlesioned side, 28 days after lesion: Stereological TH+ neuronal counts; approximately 50% neuronal loss reported in Results; no exact survival percentage inferred from bars. — Results first subsection; Figure 1B,D and caption
Pooled systemic isradipine treatment · Results first subsection; Figure 1B,D,E; Methods Animals, Isradipine treatment and plasma concentration measurement
Chronic systemic isradipine reduces dendritic calcium signals
Animal study · Juvenile male mouse SNc dopamine neurons after systemic dosing; ex vivo brain-slice dendritic calcium imaging and pacemaking recordings [3]
After 7–10 days of systemic isradipine, dendritic calcium oscillations were reduced without a discernible pacemaking-rate change. Calcium oscillations returned to control levels 5–7 days after pump removal.
Conditions shared by the study groups
- Route
- Subcutaneous osmotic minipumps
- Frequency
- Continuous delivery
- Treatment course
- 7–10 days
- Vehicle
- 50% DMSO/15% PEG300/double-distilled water
- Chronic systemic isradipine
- Model: Juvenile male mouse SNc dopamine neurons after systemic dosing; ex vivo brain-slice dendritic calcium imaging and pacemaking recordings
- Reported limits: Control dendritic values are reused from Figure 2, not a separately randomized concurrent group stated for Figure 4. Salt, stereochemical composition and pump-drug supplier not established in the selected sections.
Methods and source locations
Compound reported in the paper: Isradipine; Compound label in the paper: isradipine
Applies to the named isradipine tested in this model. No salt conversion, stereoisomer equivalence or validation of the current Adooq lot is inferred.
Results chronic-treatment paragraphs around Figure 4; Figure 4B–F; Methods Chronic isradipine treatment, Animals and imaging
Peak and average proximal and distal dendritic calcium during SNc neuronal pacemaking: Whole-cell recording plus Fura-2 two-photon imaging; Figure 4E–F uses box plots; one-tailed Mann–Whitney U test with Dunn correction. Values not reconstructed from boxes. — Results chronic-treatment section; Figure 4D–F and caption; Methods imaging and Statistics
Autonomous SNc dopamine-neuron spike rate after chronic treatment: Perforated-patch recording; Figure 4B–C. — Figure 4B–C and caption; Results chronic-treatment section
Dendritic calcium oscillations after removal of the isradipine pump: Same calcium-imaging design; washout comparison in Figure 4E–F. — Figure 4D–F and caption; Results paragraph on removal of isradipine pumps; Methods Chronic isradipine treatment
Chronic systemic isradipine · Results chronic-treatment paragraphs around Figure 4; Figure 4B–F; Methods Chronic isradipine treatment, Animals and imaging